Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aurelius Omlin

Showing results (41-50 of 98) with videos related to

Pageof 10
Sort By:
Plos One|August 3, 2017
Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancerKathrin Endt, Jens Goepfert, Aurelius Omlin, et al.
Oncotarget|March 15, 2018
Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancerChristian D Fankhauser, Peter J Schüffler, Silke Gillessen, et al.
Radiology|June 26, 2019
Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the ArtRaquel Perez-Lopez, Nina Tunariu, Anwar R Padhani, et al.
European Urology|January 15, 2013
Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomogramsAurelius Omlin, Carmel Pezaro, Deborah Mukherji, et al.
European Journal of Cancer (Oxford, England : 1990)|August 25, 2012
A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumoursSilke Gillessen, Ulrike S Gnad-Vogt, Elisa Gallerani, et al.
Cancer|July 5, 2014
Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratioArnoud J Templeton, Carmel Pezaro, Aurelius Omlin, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 6, 2019
Impact of <sup>68</sup>Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancerDaniela A Ferraro, Helena I Garcia Schüler, Urs J Muehlematter, et al.
Radiology|January 26, 2016
Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate CancerRaquel Perez-Lopez, David Lorente, Matthew D Blackledge, et al.
ESMO Open|July 17, 2020
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinomaStefanie Aeppli, Eric Innocents Eboulet, Tim Eisen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2020
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid TumorsRichard D Baird, Constanza Linossi, Mark Middleton, et al.
Pageof 10

Showing results (41-50 of 98) with videos related to

Sort By:
Pageof 10
Plos One|August 3, 2017
Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancerKathrin Endt, Jens Goepfert, Aurelius Omlin, et al.
Oncotarget|March 15, 2018
Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancerChristian D Fankhauser, Peter J Schüffler, Silke Gillessen, et al.
Radiology|June 26, 2019
Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the ArtRaquel Perez-Lopez, Nina Tunariu, Anwar R Padhani, et al.
European Urology|January 15, 2013
Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomogramsAurelius Omlin, Carmel Pezaro, Deborah Mukherji, et al.
European Journal of Cancer (Oxford, England : 1990)|August 25, 2012
A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumoursSilke Gillessen, Ulrike S Gnad-Vogt, Elisa Gallerani, et al.
Cancer|July 5, 2014
Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratioArnoud J Templeton, Carmel Pezaro, Aurelius Omlin, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 6, 2019
Impact of <sup>68</sup>Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancerDaniela A Ferraro, Helena I Garcia Schüler, Urs J Muehlematter, et al.
Radiology|January 26, 2016
Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate CancerRaquel Perez-Lopez, David Lorente, Matthew D Blackledge, et al.
ESMO Open|July 17, 2020
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinomaStefanie Aeppli, Eric Innocents Eboulet, Tim Eisen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2020
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid TumorsRichard D Baird, Constanza Linossi, Mark Middleton, et al.
Pageof 10